top of page

AI-Driven Aggregate Reporting: How Gen AI Speeds Up Compliance Documentation


In the highly regulated world of pharmacovigilance, aggregate reports—such as Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Development Safety Update Reports (DSURs)—are vital tools for evaluating the safety profile of medicinal products over time. These reports serve as a comprehensive synthesis of safety data and play a critical role in regulatory compliance and patient safety.

However, generating these reports is labor-intensive, time-consuming, and often subject to human variability. Enter Generative AI (Gen AI)—a transformative technology that is reshaping how pharmaceutical companies produce, validate, and submit aggregate safety documentation.

In this blog, we explore how Gen AI is revolutionizing aggregate reporting, reducing manual workload, increasing accuracy, and accelerating compliance timelines in pharmacovigilance.


What Is Aggregate Reporting in Pharmacovigilance?

Aggregate reporting involves the periodic submission of safety summaries to health authorities, combining data from multiple Individual Case Safety Reports (ICSRs) and other sources. Key types of aggregate reports include:

  • PBRERs/PSURs: Summarize post-marketing safety data and benefit-risk analysis.

  • DSURs: Provide safety information during a drug’s development phase.

  • Annual Safety Reports (ASRs): Mandated in certain regulatory regions like the U.S.

  • Addendum to Clinical Overview (ACO): Used in marketing authorization applications.

These reports must adhere to stringent guidelines (e.g., ICH E2C(R2), GVP Module VII), include quantitative and qualitative data, and follow a structured narrative format. The complexity of these documents, combined with increasing regulatory demands, has made their preparation a significant bottleneck in pharmacovigilance operations.


Challenges in Traditional Aggregate Reporting

Traditional methods of generating aggregate reports present numerous challenges:

1. Manual Data Compilation

Data is pulled from various systems—safety databases, literature, clinical trials, and product registries. This process is often manual, prone to errors, and time-consuming.

2. Narrative Authoring Bottlenecks

Safety scientists and medical writers must interpret and summarize large volumes of data into clear, regulatory-compliant narratives—a task requiring both domain expertise and writing skills.

3. Quality and Consistency Issues

Different authors may interpret or phrase findings differently, affecting consistency and potentially leading to regulatory queries.

4. Tight Deadlines

Aggregate reports are often produced under pressure to meet periodic regulatory submission timelines, leaving little room for error or inefficiency.

5. Resource Intensive

Preparation may require collaboration across departments—pharmacovigilance, regulatory affairs, medical writing, and data management—driving up costs and coordination effort.


Enter Generative AI: A Game-Changer for Aggregate Reporting

Generative AI (Gen AI) refers to AI models capable of producing human-like text, images, and other content. In the context of pharmacovigilance, Gen AI models like OpenAI’s GPT, Google’s Med-PaLM, and domain-specific tools can:

  • Generate structured safety narratives

  • Summarize case-level and aggregate data

  • Perform linguistic normalization

  • Automate literature extraction

  • Ensure terminology compliance (e.g., MedDRA, WHO-DD)

By automating both data synthesis and narrative generation, Gen AI transforms aggregate reporting from a manual task into a streamlined, intelligent process.


How Gen AI Enhances Aggregate Reporting

1. Automated Literature Summarization

Regulatory authorities expect aggregate reports to include information from scientific literature. Gen AI tools can rapidly scan, extract, and summarize relevant findings from journals, case reports, and reviews, ensuring comprehensive and up-to-date references with minimal effort.

Example: Instead of manually reading 200 abstracts, Gen AI summarizes findings in seconds, highlighting adverse events, patient outcomes, and study limitations.

2. Narrative Generation and Formatting

Writing sections like benefit-risk evaluation, cumulative case analysis, and risk minimization measures can be repetitive yet nuanced. Gen AI can generate first drafts using pre-approved templates and data inputs, reducing writing time and ensuring regulatory alignment.

Example: A PBRER benefit-risk section draft is generated by the AI based on cumulative data, MedDRA-coded events, and efficacy updates.

3. Data Integration from Multiple Sources

Gen AI can interact with structured and unstructured data across:

  • Safety databases (e.g., Argus, ARISg)

  • Clinical trial systems (e.g., CTMS)

  • Literature repositories (e.g., PubMed)

  • Regulatory platforms

This allows for dynamic report generation where updates can be made in real time based on the latest data pulls.

4. Enhanced Quality Control and Consistency

AI ensures that terminology, structure, and tone remain consistent across documents, reducing the likelihood of inconsistencies that can lead to regulatory queries.

Example: All safety narratives use the same template structure, approved MedDRA terms, and consistent risk language.

5. Faster Turnaround Time

By automating repetitive and time-consuming tasks, Gen AI can reduce the overall time to produce a PBRER or DSUR by up to 60%, freeing teams to focus on analysis rather than assembly.


Real-World Example: Gen AI in Action

Case Study: Mid-Sized Pharma Company Automates PBRER Generation

A mid-sized European pharmaceutical company implemented a Gen AI tool for PBRERs. Key outcomes:

  • Time savings: Average report preparation time dropped from 3 weeks to 5 days.

  • Reduced resource dependency: Medical writing staff was able to handle 2x more reports.

  • Improved quality: Regulatory feedback on narrative quality decreased by 40%.

This case highlights the potential ROI and operational scalability Gen AI provides in a real-world setting.


Regulatory Considerations for Gen AI in Reporting

While the technology is promising, compliance remains paramount. Companies must ensure that:

  1. Audit Trails: AI-generated content is traceable, with logs detailing data sources and version history.

  2. Human Oversight: Final narratives must be reviewed and approved by qualified professionals.

  3. Validation: AI tools used for regulated tasks must be validated per GxP requirements.

  4. Transparency: Regulatory agencies may ask for documentation about AI usage in submission preparation.

Many regulators are receptive to automation but require transparency about the scope and controls in place.


Best Practices for Implementing Gen AI in Aggregate Reporting

  1. Start Small: Begin with automating literature summaries or benefit-risk narratives, then expand.

  2. Define Templates: Use standardized templates to ensure consistent outputs across reports.

  3. Involve Stakeholders: Include PV, regulatory, QA, and IT in the implementation process.

  4. Validate the Output: Regularly benchmark AI output against human-written narratives for accuracy and compliance.

  5. Train the Model: Fine-tune AI tools using historical reports to align outputs with organizational tone and regulatory expectations.


The Human + AI Model: Augmented Intelligence

The goal is not to replace pharmacovigilance professionals but to augment their capabilities. Gen AI serves as a writing assistant, data processor, and knowledge synthesizer—freeing experts to focus on interpretation, strategic analysis, and scientific review.

In essence, Gen AI doesn’t replace human intelligence but enhances it—making teams faster, more informed, and more efficient.


Future Trends: What’s Next for Gen AI in Aggregate Reporting?

  1. Multilingual Reporting: Gen AI will support report generation in multiple languages, aiding global submissions.

  2. Voice-Driven Reporting: Medical reviewers might dictate insights, with Gen AI converting them into narrative sections.

  3. Real-Time Compliance Dashboards: AI-driven platforms will offer real-time status updates, highlighting gaps in data or deviations from templates.

  4. Predictive Analytics: AI could forecast safety trends based on aggregate data, proactively flagging issues before they arise.

  5. Integration with Regulatory Portals: Seamless submissions to platforms like EudraVigilance and FDA’s FAERS through API-based AI systems.


Conclusion:

The Future Is Automated, Intelligent, and Compliant

Aggregate reporting is a critical pillar of pharmacovigilance that ensures regulatory compliance and patient safety. Yet the traditional methods of preparing these reports are no longer sustainable in today’s fast-paced, data-rich environment.

Generative AI offers a practical, powerful, and scalable solution—automating time-consuming tasks, improving data quality, and accelerating report generation. When used responsibly and in combination with expert oversight, Gen AI empowers pharmacovigilance teams to achieve faster, smarter, and more compliant aggregate reporting.

Comments

bottom of page